Literature DB >> 3883743

Optimum effectiveness of intestinal alpha-glucosidase inhibitors: importance of uniform distribution through a meal.

K O'Dea, J Turton.   

Abstract

A major barrier to the widespread clinical use of an alpha-glucosidase inhibitor such as Acarbose, is the unpleasant gastrointestinal symptoms of carbohydrate malabsorption associated with its use. Acarbose is usually administered as a tablet and eaten with the first mouthful of the meal, making its uniform distribution through the meal unlikely. In the present study, Acarbose was crushed to a powder and mixed through a test meal before it was consumed. Six healthy young men consumed test meals containing 75 g carbohydrate either as whole brown rice or as ground brown rice. When Acarbose was uniformly mixed through a ground rice meal prior to digestion it produced dose-dependent reductions in the postprandial glucose, insulin and GIP responses which were evident at doses as low as 12.5 mg. The responses to whole brown rice were intermediate between those to 12.5 and 25 mg Acarbose in ground brown rice. In tablet form Acarbose was only one quarter as effective in flattening the post prandial glucose and insulin responses as it was in powder form. These results highlight the importance of uniform distribution of Acarbose through a carbohydrate meal in order to achieve maximum effectiveness in delaying digestion and absorption and yet not promoting carbohydrate malabsorption.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3883743     DOI: 10.1093/ajcn/41.3.511

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  6 in total

1.  Effect of acarbose on carbohydrate tolerance during administration of a fibre-free formula diet on healthy subjects.

Authors:  I E Walter-Sack; A Ittner-Holland; G Wolfram; N Zoellner
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 2.  Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  S P Clissold; C Edwards
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

Review 3.  A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.

Authors:  F Santeusanio; P Compagnucci
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

Review 4.  Targeting glucose metabolism for healthy aging.

Authors:  Rachel A Brewer; Victoria K Gibbs; Daniel L Smith
Journal:  Nutr Healthy Aging       Date:  2016-10-27

5.  Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity.

Authors:  Ulf Holmbäck; Anders Forslund; Stefan Grudén; Göran Alderborn; Arvid Söderhäll; Per M Hellström; Hans Lennernäs
Journal:  Obes Sci Pract       Date:  2020-02-07

6.  The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer.

Authors:  Rachael M Orlandella; William J Turbitt; Justin T Gibson; Shannon K Boi; Peng Li; Daniel L Smith; Lyse A Norian
Journal:  Cancers (Basel)       Date:  2020-10-06       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.